ByteDance Tests Drug Discovery Spinoff as AI-for-Science Ambitions Meet Commercial Reality
The social media giant is separating its pharmaceutical AI unit and seeking outside capital while retaining control - a model that could define how platform companies monetize research infrastructure.
























